Skip to main content

Table 1 Details of study populations

From: Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis

Study name Study Type (Cohort name)   Study period Age (Mean) of participants Sex (Male (%)) Primary outcome(Disease) Location Study size(N)   Race/ethnicity (%) Average follow up(years) Total Events Method for eGFR (< 60 ml/min/1.73m2)
Atta, 2006 [8] Cohort   1995-2004 42.8 58 HIVAN MD, USA 263   96(B) 8.0 36 MDRD
Buskin, 2009 [9] Cohort   1996-2003 36.5   HIVAN USA 59705   6.2(W) 3.5 5042 MDRD
           11.5(B)    
           7.3(H/L)    
           6.5(A/PI)    
           9.7(NA/AN)    
           4.7(O)    
Campbell, 2009 [10] cross-sectional   1998-2005   -- CKD BT, UK 3439   NR -- 81 MDRD
Crane, 2007 [4] Cohort(UWHIV)   2001-2006 41 83 Kidney dysfunction WA, USA 445   61(W) -- 51 CG
           23(AA)    
           16(O)    
Crum-Cianflone, 2010 [11] cross-sectional   2004-2005 41 92 Kidney dysfunction CA, MD, USA 717   48.7 (C) -- 22 MDRD
           37.9(AA)    
           13.4 (O)    
Deti, 2010 [7] Cohort(ANRS CO3)   2004-2008 43 75 CRF France 2613   NR 3.4   MDRD
Franceschini, 2006 [12] Cohort   2000-2002 40 69 ARF NC, USA 705   66(AA) 3.0   serum creatinine
Franey, 2009 [13] Cohort   2004-2007 36 31.2 RI South Africa 2189   NR -- 287 MDRD
Ganesan, 2010 [14] Cohort (P)   1986-2008 29 92 CKD USA 4044   45(AA) 6.5 90 MDRD
           44(EA)    
Heffelfinger, 2006 [15] Cohort   2000-2003 -- -- RI USA 11362   NR   724 serum creatinine
Horberg, 2010 [3] Cohort(KP)   2002-2005 43 86.1 Tubular dysfunction CA, ML, VA, USA 1647   24.5(B) 2.0   MDRD
Ibrahim, 2010 [2] Cohort(KCH)   1999-2008 37 62 ARF SL, UK 2556   55.4(B) -- 184 MDRD
           44.6(W/O)    
Jacobson, 2007 [16] Cohort(MACS)      Proteinuria USA 1203   (B)   120  
Jones, 2004 [17] Cohort(CWS)      Renal dysfunction UK 4183   NR   1175 serum creatinine > 120
Krawczyk, 2004 [18] Cohort(HOPS)   1992-2002 43 82.5 CRF GA, USA 6361   43.8(W/NH)   108 --
           5.0(H)    
           48.8(B)    
           2.5(O)    
Longenecker, 2009 [19] Cohort(P)   2004-2007 41 68 CKD CA, USA 554   42(AA) 5.0   CKD-EPI
           48(W)    
           10(O)    
Lucas, 2007 [20] Cohort(ALIVE/JHHC)   1988-2005 37 68 ESRD/RRT MD, USA 6255   (AA) 5.7 221 MDRD
Mocroft, 2010 [21] Cohort(EuroSIDA)   2004-2008 43 75.1 CKD Europe, Israel, Argentina    85.5(W) 3.7 225 CG
Reisler, 2005 [22] Cohort(MACS)   2003-2004 -- -- CKD USA 1470   NR   53 MDRD
Roe, 2008 [23] Cohort (R)   1998-2005 35.9 64 ARF SEL, UK 2274   64(B) 8.0 130 MDRD
           36(NB)    
Szczech, 2002 [24] Cohort(WIHS)    40 --    2059   71.4(B)   671.0 double serum creatinine
           16.7(W)    
           11.9(H)    
           0(O)    
Vanig, 2008 [25] Cohort (R)   2006-2007 -- 94 CKD USA 375   NR    MDRD
Wei, 2003 [26] Cohort(P)    37.6 93.2 HIVAN NY, USA 44   (AA)   44  
  Study group1   Study group2     
  Study description Sample size (n1) Event1 Incidence(per 1000py)   Study description   Sample size (n2) Event2 Incidence(per 1000py) HR/RR/OR 95% CI
Study name             
Atta, 2006 [8] ART -- 26 --   Treatment naïve   -- 10 -- 0.3 0.09, 0.98
Buskin, 2009 [9] Indinavir      Treatment naïve      1.15 1.02, 1.29
  Ritonavir      Treatment naïve      0.87 0.77, 0.98
  HAART      Treatment naïve      0.3 0.27, 0.34
Campbell, 2009 [10] Age > = 50 years(Indinavir)   -- --   Age < 50 years    -- -- 4.92 1.31, 18.4
  Indinavir/per year           1.29 1.00, 1.65
  Age > = 50 years(Tenofovir)      Age < 50 years      5.42 1.71, 16.8
Crane, 2007 [4] Age (30-40) years      Age < 30 years      0.9 0.2, 3.2
  Age (40-50) years      Age < 30 years      2.1 0.6, 7.6
  Age > 50 years      Age < 30 years      4.4 1.1, 17.2
  (NRTI)Didanosine      (NRTI)lamivudine/emtricitabine      3.1 1.40, 6.80
  PI(Amprenavir/fos-amprenavir)      NNRTI (efavirenz)      3.6 1.00, 12.5
Crum-Cianflone, 2010 [11] Age/10 year increase           1.99 1.22, 3.24
  Tenofovir/per year           1.54 1.10, 2.15
Deti, 2010 [7] Age/10 year increase           2.2 1.8, 2.6
  CD4 < 200 cells/mm3      CD4 > 500 cells/mm3      4.04 2.3, 7.1
  Tenofovir/per year           1.4 1.1, 1.8
Franceschini, 2006 [12] CD4 < 200 cells/mm3      CD4 > = 200 cells/mm3      4.7 2.5, 8.8
Franey, 2009 [13] CD4 < 100 cells/mm3      CD4 > 100 cells/mm3      1.4 1.07, 1.82
  Age > 40 years      Age < 40 years      4.65 3.54, 6.10
Ganesan, 2010 [14] Age > = 35 years      Age < 35 years      2.6 1.7, 4.0
  CD4 < = 200 cells/mm3      CD4 > = 500 cells/mm3      6.8 3.0, 15.5
  CD4(201-349) cells/mm3      CD4 > = 500 cells/mm4      4.3 2.3, 8.1
  CD4(350-499) cells/mm3      CD4 > = 500 cells/mm5      2.4 1.3, 4.6
Heffelfinger, 2006 [15] Tenofovir      Treatment naïve      1.5 1.1, 1.9
Horberg, 2010 [3] Tenofovir 964     Non-Tenofovir   683    5.23 2.08, 13.1
Ibrahim, 2010 [2] Age/10 year increase           1.04 0.87, 1.24
  Indinavir      Treatment naïve      1.81 0.53, 6.76
  Tenofovir      Treatment naïve      1.06 0.46, 2.43
  Atazanavir      Treatment naïve      1.05 0.20, 5.49
  CART      Treatment naïve      1.11 0.54, 2.30
  CD4(201-350) cells/mm3      CD4 > 350 cells/mm3      1.56 0.97, 2.48
  CD4(101-200) cells/mm3      CD4 > 350 cells/mm3      2.08 1.11, 3.91
  CD4(51-100) cells/mm3      CD4 > 350 cells/mm3      6.38 3.18, 12.78
  CD4(0-50) cells/mm3      CD4 > 350 cells/mm3      10.29 5.11, 20.98
Jacobson, 2007 [16] HIV 94     Non-HIV   26    5.1 2.9, 8.9
Jones, 2004 [17] Tenofovir 1058 84    Treatment naïve      0.22 0.07, 0.69
Krawczyk, 2004 [18] CD4 < 200 cells/mm3      200-349 cells/mm3      4.3 2.1, 8.7
  HAART      Treatment naïve      0.5 0.3, 1.0
Longenecker, 2009 [19] HIV 337 26    Non-HIV   230 2   6.5 1.5, 28.7
  Age/10 year increase           1.34 1.02, 1.77
Lucas, 2007 [20] AIDS 1902 125 12.7   No AIDS   2607 51 4.7 2.7 1.9, 4.0
  Age(30-49.9)      Age < 30 years      1.5 0.7, 3.3
  Age > = 50 years      Age < 30 years      2 0.8, 4.7
  AIDS 1902    Non-HIV   1751    5.1 3.5, 7.6
  HIV 2607     Non-HIV   1751    2.3 1.5, 3.5
Mocroft, 2010 [21] AIDS      No AIDS      2.22 1.14, 4.32
  Age/10 year increase           1.54 1.31, 1.80
  Tenofovir/per year           1.16 1.06, 1.25
  Indinavir/per year           1.12 1.06, 1.18
  Atazanavir/per year           1.21 1.09, 1.34
  Lopinavir/r per year           1.08 1.01, 1.16
Reisler, 2005 [22] HIV   32    Non-HIV    21   2.5 1.4, 4.5
  Tenofovir      Non-Tenofovir      2 0.8, 4.9
Roe, 2008 [23] CD4 < 100 cells/mm3      CD4 > 200 cells/mm3      6.75 2.5, 18.3
  CD4(100-199) cells/mm3      CD4 > 200 cells/mm3      3.02 0.99, 9.13
  AIDS      No AIDS      6.7 3.4, 13.3
Szczech, 2002 [24] CD4 < = 200 cells/mm3      CD4 > 200 cells/mm3      3.57 1.72, 7.14
Vanig, 2008 [25] Tenofovir 253     Non-Tenofovir   122    1.83 1.11, 3.02
  PI      Non-PI      1.27 0.84, 1.91
Wei, 2003 [26] ART      Treatment naïve      1.51 0.37, 6.20
  CD4 < = 100 s cell/mm3      CD4 > = 100 cells/mm3      2.73 0.82, 9.14
  1. A, Asian; AA, African-American; B, Black; EA, European American; H, Hispanic; NH, Non-Hispanic; L, Latino; NB, Non-b lack; PI, Pacific Islander; NA, Native American; AN, Alaska Native; W, White; O, Others; MD, Maryland; NC, North Carolina; WA, Washington; GA, Georgia; SL South London; SEL, Southeast London; BT, Brighton; NR, Not Reported; NA, Not Applicable; Sr, Serum; R, Retrospective; P, Prospective; WIHS, Women's Interagency HIV Study; UWHIV, University of Washington HIV; ALIVE, AIDS Link to the Intravenous Experience; JHHC, Johns Hopkins HIV Cohort; KP, Kaiser Permanente; MACS, Multicentre AIDS Cohort Study; CWS, Chelsea and Westminster; HOPS, HIV Outpatient Study; KCH, Kings College Hospital; ANRS CO3, National agency for AIDS research Aquitaine Cohort; MDRD, Modification of Diet in Renal Disease-an equation to estimate GFR that incorporates serum creatinine, age, sex and race; CG, Cockcroft-Gault equation to estimate GFR that incorporates serum creatinine, age, sex and weight; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration-an equation that take into account serum creatinine, age, sex and race.